Repligen Corp

Day range

$174.90 – $179.54

Open

$178.30

Prev close

$176.93

Volume

1.07M

Market cap

$11.35B

Shares out

56.44M

P/E

273.15

P/S

14.45

P/B

5.37

P/FCF

101.34

ROE

2.0%

ROA

1.4%

Debt/Equity

0.26

Div yield

0.00%

As of Oct 22, 2026

• Equity activityOct 6, 2026

  Each share of BioLife's common stock ... converted automatically into the right to receive (A) 0.1442 validly issued, fully paid and nonassessable shares of Repligen common stock ... and (B) $11.25 in cash.

• Board of directorsSep 15, 2026

  On September 10, 2026, Karen A. Dawes notified Repligen Corporation ("Repligen") that she will be retiring from the Repligen Board of Directors (the "Board") after over twenty years of distinguished service to Repligen, effective as of September 30, 2026. Ms. Dawes's decision to retire from the Board is not the result of any disagreement with Repligen with respect to Repligen's operations, policies or procedures.

• Shareholder meetingsSep 8, 2026

  The completion of the Mergers remains subject to the satisfaction of other customary closing conditions specified in the Merger Agreement, including the adoption of the Merger Agreement by BioLife's stockholders. ... the special meeting of BioLife stockholders to consider adoption of the Merger Agreement has been scheduled to be held ... on October 5, 2026 at 9:00 a.m. Eastern Time.

• Deal agreementsJul 22, 2026

  On July 21, 2026, Repligen Corporation, a Delaware corporation ('Repligen'), entered into an Agreement and Plan of Merger (the 'Merger Agreement') by and among Repligen, Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen ('Merger Sub 1'), Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen ('Merger Sub 2'), and BioLife Solutions, Inc., a Delaware corporation ('BioLife'), pursuant to which Repligen will acquire, subject to the satisfaction or waiver of the conditions contained in the Merger Agreement, all of the outstanding shares of BioLife's common stock, par value $0.001 per share ('BioLife Common Stock'), for $11.25 cash and 0.1442 shares of Repligen's common stock, on a per share basis.

• Shareholder meetingsMay 15, 2026

  On May 14, 2026, Repligen Corporation held its 2026 Annual Meeting of Stockholders. At the 2026 Annual Meeting, the Company's stockholders voted on the following proposals: (i) to elect the nine (9) director nominees to the Company's Board of Directors; (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and (iii) to consider and act upon a non-binding, advisory vote to approve the compensation of the Company's named executive officers. Each of the director nominees in proposal 1 were duly elected by, and each of proposals 2 and 3 were approved by, the Company's stockholders at the 2026 Annual Meeting.

• DHRDanaher Corporation+0.00%
• TMOThermo Fisher Scientific, Inc.+0.00%
• AAgilent Technologies Inc.+0.00%
• RVTYRevvity, Inc.+0.00%
• WATWaters Corp+0.00%
• MTDMettler-Toledo International+0.00%
• BIOBio-Rad Laboratories, Inc.Class A+0.00%

Days to cover

6.6

Short interest

7.58M

Avg volume

1.15M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR
  positiveGlobeNewswire Inc.· Oct 1, 2026
• Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
  positiveZacks Investment Research· Sep 22, 2026
• Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing
  positiveGlobeNewswire Inc.· Sep 15, 2026
• Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
  positiveZacks Investment Research· Sep 2, 2026
• Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
  positiveZacks Investment Research· Sep 2, 2026